Plural Ring Hetero Atoms In The Bicyclo Ring System, Or Ring Nitrogen Is Shared By The Two Cyclos Of The Bicyclo Ring System Patents (Class 548/453)
-
Publication number: 20140252278Abstract: Disclosed is a p-type organic semiconductive material that is easy to produce and that has a high planarity in its polymer skeleton, and also provides a photoelectric conversion material, a photoelectric conversion layer, a photoelectric conversion element, and an organic thin film solar cell each having high photoelectric conversion efficiency and using the p-type organic semiconductive material. Specifically, the invention provides a bibenzo[b]furan compound having at least one constitutional unit represented by the following formula (1) or (2), as well as a photoelectric conversion material, a photoelectric conversion layer, a photoelectric conversion element, and an organic thin film solar cell each using that compound for a p-type organic semiconductive material.Type: ApplicationFiled: October 22, 2012Publication date: September 11, 2014Applicant: Adeka CorporationInventors: Mineki Hasegawa, Toru Yano, Ryo Taniuchi
-
Patent number: 8822449Abstract: The invention relates to substituted aminoindanes and analogs thereof of formula (I) and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders.Type: GrantFiled: August 25, 2009Date of Patent: September 2, 2014Assignee: SanofiInventors: Nils Rackelmann, Laurent Bialy, Heinrich Englert, Klaus Wirth, Petra Arndt, John Weston, Uwe Heinelt, Markus Follmann
-
Publication number: 20140243492Abstract: The invention addresses a problem of purifying a monomer to be a precursor according to a simpler and milder method so as to obtain a polymer having a higher molecular weight. The invention relates to a method for producing a condensed polycyclic aromatic compound having n active groups (wherein n is an integer of 1 or more and 4 or less), which comprises bringing a composition containing the condensed polycyclic aromatic compound and a solvent into contact with zeolite.Type: ApplicationFiled: May 2, 2014Publication date: August 28, 2014Applicant: MITSUBISHI CHEMICAL CORPORATIONInventors: Rieko FUJITA, Jyunya Kawai, Wataru Sato, Kenichi Satake, Mitsunori Furuya
-
Patent number: 8815933Abstract: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.Type: GrantFiled: February 7, 2014Date of Patent: August 26, 2014Assignee: Forum Pharmaceuticals, Inc.Inventors: Richard Chesworth, Gideon Shapiro, Gerhard Koenig
-
Publication number: 20140217329Abstract: The present invention relates to compositions, comprising (a) a compound of the formula (I), and (b) a polymeric material, to specific oligomers of the formula I, and their use as organic semiconductor in organic devices, especially in organic photovoltaics (solar cells) and photodiodes, or in a device containing a diode and/or an organic field effect transistor. High efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the compositions, or oligomers according to the invention are used in organic field effect transistors, organic photovoltaics (solar cells) and photodiodes.Type: ApplicationFiled: August 31, 2012Publication date: August 7, 2014Applicants: Universite Libre de Bruxelles, BASF SEInventors: Pascal Hayoz, Natalia Chebotareva, Yves Henri Geerts, Sara Stas, Jean-Yves Balandier
-
Publication number: 20140217374Abstract: Novel compounds useful as organic semiconductor material are described. Semiconductor devices containing said organic semiconductor material are also described.Type: ApplicationFiled: May 18, 2012Publication date: August 7, 2014Applicant: E.T.C. S.R.L.Inventors: Manuela Melucci, Laura Favaretto, Massimo Zambianchi, Raffaella Capelli, Michele Muccini
-
Publication number: 20140221420Abstract: Compounds that modulate the CCR5 chemokine receptor, pharmaceutical compositions containing them, and uses therefor in the treatment of HIV and related diseases are described.Type: ApplicationFiled: March 18, 2011Publication date: August 7, 2014Applicant: PURDUE RESEARCH FOUNDATIONInventors: Arun K. Ghosh, Hiroaki Mitsuya, Venkateswararao Kalapala, Jianfeng Li
-
Patent number: 8796469Abstract: The present invention relates to polymers comprising one or more (repeating) unit(s) of the formula (I) which are characterized in that Ar1 and Ar1? are independently of each other are an annulated (aromatic) heterocyclic ring system, containing at least one thiophene ring, which may be optionally substituted by one, or more groups, and their use as organic semiconductor in organic devices, especially in organic photovoltaics (solar cells) and photodiodes, or in a device containing a diode and/or an organic field effect transistor. The polymers according to the invention have excellent solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in organic field effect transistors, organic photovoltaics (solar cells) and photodiodes.Type: GrantFiled: March 22, 2010Date of Patent: August 5, 2014Assignee: BASF SEInventors: Pascal Hayoz, Olivier Frédéric Aebischer, Mathias Düggeli, Hans Jürg Kirner, Marta Fonrodona Turon
-
Patent number: 8796262Abstract: This invention relates to new fused heterocyclic derivatives having affinity to S1P receptors, a pharmaceutical composition containing said compounds, as well as the use of said compounds for the preparation of a medicament for treating, alleviating or preventing diseases and conditions in which any S1P receptor is involved or in which modulation of the endogenous S1P signaling system via any S1P receptor is involved.Type: GrantFiled: July 8, 2011Date of Patent: August 5, 2014Assignees: AbbVie B.V., AbbVie Inc.Inventors: Pieter Smid, Wouter I. Iwema Bakker, Hein K. A. C. Coolen, Leonardus A. J. M. Sliedregt, Maria J. P. van Dongen, Jacobus A. J. den Hartog, Adrian Hobson
-
Patent number: 8785477Abstract: Hexahydropyrrolo[3,4-b]pyrrole derivatives, preparation methods and pharmaceutical uses thereof are provided. Specifically, dipeptidyl peptidase IV inhibitors presented by following formula (I) are provided. Such compounds can be used for treating or preventing the diseases associated with dipeptidyl peptidase IV, such as diabetes, obesity and hyperlipemia. The compounds presented by formula (I) and pharmaceutically acceptable salts thereof, a method for preparing a pharmaceutical composition thereof and their uses in the manufacture of medicaments for treating or preventing the disease associated with dipeptidyl peptidase IV are provided.Type: GrantFiled: November 26, 2012Date of Patent: July 22, 2014Assignee: Shanghai Sun-Sail Pharmaceutical Science & Technology Co., Ltd.Inventors: Peng Lu, Rui Zhang, Wansong Yu, Mingjie Zhu, Yilang Chen
-
Patent number: 8758880Abstract: Monomeric or polymeric compounds comprising at least one moiety of the formula (Ia) wherein X is CR, where R is H or a substituent as defined in claim 1, or is another ketopyrrole moiety e.g. of the formula (Ib) or (Ic) with this moiety and all other symbols are as defined in claim 1, show good solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).Type: GrantFiled: October 16, 2008Date of Patent: June 24, 2014Assignee: BASF SEInventors: Jean-Charles Flores, Ulrich Berens, Frank Bienewald, Hans Jürg Kirner, Mathieu G. R. Turbiez
-
Publication number: 20140166987Abstract: Conjugated polymers and small molecules including the nonplanar aromatic 1,6-methano[10]annulene ring structure along with aromatic subunits, such as diketopyrrolopyrrole, and 2,1,3-benzothiadiazole, substituted with alkyl chains in a “Tail In,” “Tail Out,” or “No Tail” regiochemistry are disclosed.Type: ApplicationFiled: December 14, 2012Publication date: June 19, 2014Applicant: The Johns Hopkins UniversityInventors: John D. Tovar, Benjamin C. Streifel, Patricia A. Peart
-
Patent number: 8742131Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetyl-choline receptor-mediated diseases, such as pulmonary diseases, are provided.Type: GrantFiled: January 27, 2011Date of Patent: June 3, 2014Assignee: Theron Pharmaceuticals, Inc.Inventors: Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
-
Publication number: 20140142308Abstract: Receptor type oligothiopene compounds, methods of preparing the compounds, and use of the compounds in photoelectric materials.Type: ApplicationFiled: March 27, 2012Publication date: May 22, 2014Applicant: NANKAI UNIVERSITYInventors: Yongsheng Chen, Xiangjian Wan, Yongsheng Liu, Zhi Li, Jiaoyan Zhou, Fei Wang, Guangrui He, Guankui Long
-
Patent number: 8722702Abstract: Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.Type: GrantFiled: February 25, 2013Date of Patent: May 13, 2014Assignee: Plexxikon Inc.Inventors: Jiazhong Zhang, Prabha N. Ibrahim, Dean R. Artis, Ryan Bremer, Guoxian Wu, Marika Nespi, Chao Zhang
-
Publication number: 20140128618Abstract: The present invention relates to oligomers of the formula (I), and their use as organic semiconductor in organic devices, especially in organic photovoltaics (solar cells) and photodiodes, or in a device containing a diode and/or an organic field effect transistor. High efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the oligomers according to the invention are used in organic field effect transistors, organic photovoltaics (solar cells) and photodiodes.Type: ApplicationFiled: June 20, 2012Publication date: May 8, 2014Applicant: BASF SEInventors: Pascal Hayoz, Natalia Chebotareva
-
Patent number: 8703938Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with the compounds.Type: GrantFiled: September 10, 2010Date of Patent: April 22, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Ce Wang, Lu Ying, Xiaowen Peng, Yao-Ling Qiu
-
Patent number: 8686142Abstract: 2-Aminopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.Type: GrantFiled: February 12, 2013Date of Patent: April 1, 2014Assignee: Janssen Pharmaceutica NVInventors: Frank Chavez, James P. Edwards, Brad M. Savall, Jianmei Wei, Ronald L. Wolin
-
Publication number: 20140080860Abstract: The invention relates to novel hybrid cholinesterase inhibitors containing the melatonin or its oxidation products unit and tetrahydroacridine unit linked via a carbamate bond. Due to the high selectivity of action, which is expressed with high ratio of IC50 for acetylcholinesterase inhibition to IC50 for butyrylcholinesterase inhibition ([IC50(AChE)]/[IC50(BChE)]), the novel compounds may be used in relief and/or treatment of the neurodegenerative diseases, among them the Alzheimer's disease.Type: ApplicationFiled: November 22, 2013Publication date: March 20, 2014Applicants: CENTRUM MEDYCZNE KSZTALCENIA PODYPLOMOWEGO, UNIWERSYTET WARSZAWSKIInventors: Anna Zawadzka, Zbigniew Czarnocki, Iwona Lozinska, Zuzanna Moleda, Miroslawa Panasiewicz
-
Patent number: 8673920Abstract: This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.Type: GrantFiled: April 27, 2010Date of Patent: March 18, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Aurash Shahripour, Haifeng Tang, Nardos H. Teumelsan, Lihu Yang, Yuping Zhu, Shawn P. Walsh
-
Publication number: 20140066433Abstract: The present invention relates to a fused heterocyclic derivative of the formula (I) The variables R1-R4, z, A, Q, X and Y are as defined in the claims. The following heterocycles are exemplified sub-structures of formula (I): The compounds of formula (I) are modulators of the S1P receptor (Sphingosine-1-phosphate receptor), More specifically, they are agonists of S1P5. The compounds have therapeutic use in treatment of cognitive disorders, age-relate cognitive decline and dementia.Type: ApplicationFiled: September 5, 2013Publication date: March 6, 2014Inventors: Pieter Smid, Wouter I. Iwema Bakker, Hein K.A.C. Coolen, Leonardus A.J.M. Sliedregt, Maria J.P. van Dongen, Jacobus A.J. den Hartog, Adrian Hobson
-
Publication number: 20140060636Abstract: The present invention provides for an organic compound comprising electron deficient unit covalently linked to two or more electron rich units. The present invention also provides for a device comprising the organic compound, such as a light-emitting diode, thin-film transistor, chemical biosensor, non-emissive electrochromic, memory device, photovoltaic cells, or the like.Type: ApplicationFiled: October 12, 2012Publication date: March 6, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: The Regents of the University of California
-
Patent number: 8658637Abstract: Compounds of Formula (IA) wherein R1, R2, R3, A, B, C, D, E, G, X, Y, and Z are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.Type: GrantFiled: November 29, 2007Date of Patent: February 25, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Daniel Kuzmich, Darren DiSalvo, Hossein Razavi, Michael Jason Burke
-
Patent number: 8653280Abstract: The present invention is directed to novel compounds of formula (I) as well as to the process for their preparation. Novel compounds of formula (I) can be converted into asenapine through an efficient process. The invention also relates to novel intermediates used in this process and their use in the preparation of compounds of formula (I).Type: GrantFiled: July 29, 2011Date of Patent: February 18, 2014Assignee: Laboratories Lesvi, S.L.Inventors: Pere Dalmases Barjoan, Juan Huguet Clotet, Jordi Peirats Masia
-
Patent number: 8648084Abstract: The present application describes selective ligands of formula (I) for neuronal nicotinic receptors (NNRs), more specifically for the ?4?2 NNR subtype, compositions thereof, and methods of using the same, wherein X, R1, X, R2, R3, L1, m, n, p, and q are defined in the specification.Type: GrantFiled: March 6, 2012Date of Patent: February 11, 2014Assignee: AbbVie Inc.Inventors: William H. Bunnelle, Lei Shi, Marc J. C. Scanio
-
Patent number: 8642638Abstract: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition.Type: GrantFiled: November 19, 2009Date of Patent: February 4, 2014Assignee: EnVivo Pharmaceuticals, Inc.Inventors: Richard Chesworth, Gideon Shapiro, Gerhard Koenig
-
Patent number: 8642587Abstract: The present invention relates to heterocyclic compounds of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such heterocyclic compounds, and the use of such heterocyclic compounds for therapeutic purposes.Type: GrantFiled: February 16, 2010Date of Patent: February 4, 2014Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Udo Lange, Andreas Heutling, Wilhelm Amberg, Michael Ochse, Berthold Behl, Wilfried Hornberger, Mario Mezler
-
Publication number: 20140021414Abstract: The invention relates to novel compounds based on pyrrolo[3,2-b]pyrrole-2,5-dione, methods for their preparation and intermediates used therein, mixtures and formulations containing them, the use of the compounds, mixtures and formulations as semiconductor in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these compounds, mixtures or formulations.Type: ApplicationFiled: February 28, 2012Publication date: January 23, 2014Applicant: MERCK PATENT GMBHInventors: Nicolas Blouin, William Mitchell, Amy Topley, Steven Tierney
-
Publication number: 20140011988Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.Type: ApplicationFiled: February 14, 2013Publication date: January 9, 2014Inventors: Robert Deziel, Silvana Leit, Patrick Beaulieu, Yves Andre Chantigny, John Mancuso, Pierre Tessier, Gideon Shapiro, Richard Chesworth, David Smil
-
Publication number: 20140001411Abstract: The invention relates to novel polymers containing one or more pyrrolo[3,2-b]pyrrole-2,5-dione repeating units, methods for their preparation and monomers used therein, blends, mixtures and formulations containing them, the use of the polymers, blends, mixtures and formulations as semiconductor in organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices, and to OE and OPV devices comprising these polymers, blends, mixtures or formulations.Type: ApplicationFiled: February 15, 2012Publication date: January 2, 2014Applicant: MERCK PATENT GMBHInventors: Nicolas Blouin, William Mitchell, Amy Topley, Steven Tierney
-
Publication number: 20130317024Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.Type: ApplicationFiled: May 22, 2013Publication date: November 28, 2013Applicant: NOVARTIS AGInventors: Simona Cotesta, Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Stefan Stutz, Andrea Vaupel
-
Patent number: 8592587Abstract: The disclosure relates to a method for the synthesis of a compound of the following formula (I) in which: R1 and R2 are independently an N-protective group; R3 is a hydrogen atom, a C1-C6 alkyl group, a C1-C6 arylalkyl group, a C2-C6 alkenyl group, or a alkoxycarbonylalkyl group; Y is a —C(HR4)- group in which R4 is a hydrogen atom, a C1-C6 alkyl group, an aryl group, a C1-C6 arylalkyl group, or a C2-C6 alkenyl group; or an orthophenylene group.Type: GrantFiled: March 21, 2008Date of Patent: November 26, 2013Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier IInventors: Jean Martinez, Georges Dewynter, Daniel Farran
-
Patent number: 8586609Abstract: The invention relates to aryl-substituted polycyclic amines of formula I, especially bicyclic amines, and to the physiologically tolerated salts and physiologically functional derivatives thereof; where the symbols and radicals are explained in the description, as well as to pharmaceutical compositions containing them and to methods of treatment using them.Type: GrantFiled: July 29, 2010Date of Patent: November 19, 2013Assignee: Sanofi-Aventis Deutschland GmbHInventors: Lothar Schwink, Siegfried Stengelin, Matthias Gossel, Gerhard Hessler, Petra Lennig
-
Publication number: 20130303570Abstract: The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.Type: ApplicationFiled: July 17, 2013Publication date: November 14, 2013Inventors: Hayley Binch, Lev T.D. Fanning, Dennis Hurley, Urvi Sheth, Alina Silina, Xiaoqing Yang, Martyn Botfield, Peter D.J. Grootenhuis, Fredrick Van Goor, Mehdi Michel Djamel Numa
-
Publication number: 20130296554Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.Type: ApplicationFiled: March 13, 2013Publication date: November 7, 2013Inventors: Ny Sin, Zheng Liu, Jacob Swidorski, Sing-Yuen Sit, Jie Chen, Yan Chen, Nicholas A. Meanwell, Alicia Regueiro-Ren
-
Patent number: 8569354Abstract: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.Type: GrantFiled: November 12, 2012Date of Patent: October 29, 2013Assignee: EnVivo Pharmaceuticals, Inc.Inventors: Richard Chesworth, Gideon Shapiro, Gerhard Koenig
-
Publication number: 20130280305Abstract: The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: R1 and R2 are, the same or different, alkenyl, etc, and X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and X3 is absent or is alkyl, etc, Y is absent or anion, a and b are, the same or different, 0 to 3, and L3 is a single bond, etc, R3 is alkyl, etc, L1 and L2 are —O—, —CO—O— or —O—CO—), a composition comprising the cationic lipid and a nucleic acid, and a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like.Type: ApplicationFiled: November 2, 2012Publication date: October 24, 2013Inventors: Takeshi KUBOYAMA, Tomohiro ERA, Tomoyuki NAOI, Nobuhiro YAGI
-
Publication number: 20130274278Abstract: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.Type: ApplicationFiled: June 6, 2013Publication date: October 17, 2013Inventors: Stephen M. CONDON, Yijun DENG, Matthew D. ALEXANDER, Matthew G. LAPORTE
-
Patent number: 8557859Abstract: Isolated immunomodulatory (e.g. immunostimulatory) polyhydroxlated pyrrolizidine compounds having the formula (I), wherein R is selected from the group comprising hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g. cycloalkyl), alkenyl, alkynyl and aryl groups, or a pharmaceutically acceptable salt or derivative thereof, are useful in therapy and prophylaxis, including increasing the Th1:Th2 response ratio, haemorestoration, alleviation of immuno-suppression, cytokine stimulation, treatment of proliferative disorders (e.g. cancer), vaccination, stimulation of the innate immune response and boosting of the activity of endogenous NK cells.Type: GrantFiled: January 15, 2013Date of Patent: October 15, 2013Assignee: Summit (Wales) LimitedInventors: Alison Ann Watson, Robert James Nash, Emma Louisa Evinson
-
Publication number: 20130261129Abstract: Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.Type: ApplicationFiled: March 29, 2013Publication date: October 3, 2013Applicant: AbbVie Inc.Inventors: Michael D. Meyer, Xueqing Wang, Tao Guo, Robert Wei, Lijuan Jane Wang
-
Publication number: 20130244994Abstract: This invention relates to novel compounds of the Formula (I) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds of the Formula (I) and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.Type: ApplicationFiled: February 15, 2013Publication date: September 19, 2013Inventors: David A. Claremon, Linghang Zhuang, Yuanjie Ye, Suresh B. Singh, Colin M. Tice
-
Publication number: 20130237514Abstract: Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.Type: ApplicationFiled: October 5, 2012Publication date: September 12, 2013Applicant: ChemoCentryx, Inc.Inventors: Trevor T. Charvat, Hiufung Chu, Antoni Krasinski, Christopher W. Lange, Manmohan Reddy Leleti, Jay P. Powers, Sreenivas Punna, Timothy J. Sullivan, Solomon Ungashe
-
Publication number: 20130234075Abstract: Disclose is a triphenylamine derivative with a low band gap. The triphenylamine derivative is represented by Formula (I): wherein R1 and Ar are as defined in the specification. Further disclosed is a highefficiency organic photovoltaic cell using the derivative.Type: ApplicationFiled: October 25, 2012Publication date: September 12, 2013Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Bong Soo KIM, Min Jae KO, Hong Gon KIM, Jin Young KIM, Hyo Sang LEE, Minwoo JUNG, Doh-Kwon LEE
-
Publication number: 20130225561Abstract: This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.Type: ApplicationFiled: October 21, 2011Publication date: August 29, 2013Inventors: Haifeng Tang, Alexander Pasternak, Lihu Yang, Shawn P. Walsh, Barbara Pio, Aurash Shahripour, Nardos Teumelsan
-
Patent number: 8519155Abstract: The present invention relates to the choline and tromethamine salt of Licofelone.Type: GrantFiled: October 30, 2009Date of Patent: August 27, 2013Assignee: c-a-i-r biosciences GmbHInventors: Wolfgang Albrecht, Hans-Günter Striegel, Stefan Laufer
-
Publication number: 20130216552Abstract: Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed herein.Type: ApplicationFiled: June 24, 2011Publication date: August 22, 2013Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Takashi Nakai, James Jia, Jason Rohde, Regina Graul, Ara Mermerian
-
Publication number: 20130211100Abstract: The present invention describes a method to generate new chemical entities (NCEs) that have well-defined activities such as, but not limited to, anti-bacterial, antifungal and anthelmintic effects. The NCEs are generated through adaptive evolution of one microbe (the producer) against another organism or cell type (the target). The producer is made to compete against the target over time by co-culturing the two together and serially passing the producer organism until the producer adaptively evolves by synthesizing an NCE(s) that inhibits growth of or kills the target. The molecular structure of the chemical entity (or entities) is then clucidated using tools from genomics, molecular biology, computational biology, analytical chemistry, organic chemistry and related fields.Type: ApplicationFiled: October 28, 2011Publication date: August 15, 2013Inventors: Bernhard Palsson, Pep Charusanti
-
Publication number: 20130200339Abstract: A heterocyclic compound includes a compound represented by Formula 1.Type: ApplicationFiled: October 2, 2012Publication date: August 8, 2013Applicant: SAMSUNG DISPLAY CO., LTD.Inventor: Samsung Display Co., Ltd.
-
Publication number: 20130203737Abstract: The present invention relates to a fused heterocyclic derivative of the formula (I) wherein R1 is selected from cyano, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkyl, each optionally substituted with CN or one or more fluoro atoms, (3-6C)cycloalkyl, (4-6C)cycloalkenyl or a (8-10C)bicyclic group, each optionally substituted with halogen or (1-4C)alkyl optionally substituted with one or more fluoro atoms, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, cyano, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, amino, dimethylamino, and (3-6C)cycloalkyl optionally substituted with phenyl which may be substituted with (1-4C)alkyl or halogen, and phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, Z is a linking group —W—(Cn-alkylene)-T- wherein W is attached to R1 and selType: ApplicationFiled: July 8, 2011Publication date: August 8, 2013Applicant: ABBVIE B.V.Inventors: Pieter Smid, Wouter I. Iwema Bakker, Hein K.A.C. Coolen, Leonardus A.J.M. Sliedregt, Maria J.P. van Dongen, Jacobus A.J. den Hartog
-
Patent number: 8501961Abstract: Compounds that inhibit proteolytic enzymes of Human Immunodeficiency Virus (HIV) are described. Preparation of the inhibitors, pharmaceutical compositions containing them, and uses of the compounds or compositions for the treatment of HIV infections are also described.Type: GrantFiled: July 8, 2009Date of Patent: August 6, 2013Assignee: Purdue Research FoundationInventor: Arun K. Ghosh